These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 30190915)

  • 1. The role for chemotherapy in the modern management of melanoma.
    Gupta A; Gomes F; Lorigan P
    Melanoma Manag; 2017 May; 4(2):125-136. PubMed ID: 30190915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for Melanoma.
    Wilson MA; Schuchter LM
    Cancer Treat Res; 2016; 167():209-29. PubMed ID: 26601864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic melanoma.
    Sun W; Schuchter LM
    Curr Treat Options Oncol; 2001 Jun; 2(3):193-202. PubMed ID: 12057119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of chemotherapy in the modern management of melanoma.
    Lee RJ; Ul-Ain-Tariq N; Fusi A; Bowyer S; Lorigan P
    Melanoma Manag; 2014 Nov; 1(2):173-184. PubMed ID: 30190822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of metastatic malignant melanoma.
    Atallah E; Flaherty L
    Curr Treat Options Oncol; 2005 May; 6(3):185-93. PubMed ID: 15869730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic chemotherapy in the treatment of malignant melanoma.
    Lens MB; Eisen TG
    Expert Opin Pharmacother; 2003 Dec; 4(12):2205-11. PubMed ID: 14640919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy.
    Anderson CM; Buzaid AC; Sussman J; Lee JJ; Ali-Osman F; Braunschweiger PG; Plager C; Bedikian A; Papadopoulos N; Eton O; Legha SS; Grimm EA
    Melanoma Res; 1998 Apr; 8(2):149-55. PubMed ID: 9610868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
    Flaherty LE
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.
    Legha SS; Ring S; Eton O; Bedikian A; Plager C; Papadopoulos N
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S9-15. PubMed ID: 9457387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
    Carvajal RD; Schwartz GK; Mann H; Smith I; Nathan PD
    BMC Cancer; 2015 Jun; 15():467. PubMed ID: 26059332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
    Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
    J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
    Legha SS; Ring S; Bedikian A; Plager C; Eton O; Buzaid AC; Papadopoulos N
    Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemotherapy for melanoma.
    Philip PA; Flaherty LE
    Curr Oncol Rep; 2000 Jul; 2(4):314-21. PubMed ID: 11122859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving outcomes in advanced malignant melanoma: update on systemic therapy.
    Danson S; Lorigan P
    Drugs; 2005; 65(6):733-43. PubMed ID: 15819587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the effect of biochemotherapy in metastatic malignant melanoma: an immunopathological evaluation.
    Håkansson A; Håkansson L; Gustafsson B; Krysander L; Rettrup B; Ruiter D; Bernsen MR
    Melanoma Res; 2003 Aug; 13(4):401-7. PubMed ID: 12883367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review.
    Simon A; Kourie HR; Kerger J
    Chin J Cancer; 2017 Jan; 36(1):10. PubMed ID: 28086948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.
    Eton O; Legha SS; Bedikian AY; Lee JJ; Buzaid AC; Hodges C; Ring SE; Papadopoulos NE; Plager C; East MJ; Zhan F; Benjamin RS
    J Clin Oncol; 2002 Apr; 20(8):2045-52. PubMed ID: 11956264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma.
    Harting MS; Kim KB
    Melanoma Res; 2004 Dec; 14(6):517-20. PubMed ID: 15577323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia.
    Yi JH; Yi SY; Lee HR; Lee SI; Lim DH; Kim JH; Park KW; Lee J
    Melanoma Res; 2011 Jun; 21(3):223-7. PubMed ID: 21471822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.